Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study.
Saved in:
| Title: | Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study. |
|---|---|
| Authors: | Cork MJ; Sheffield Dermatology Research, Department of Infection, Immunity & Cardiovascular Disease, University of Sheffield, Sheffield, UK.; Sheffield Children's Hospital Clinical Research Facility, Sheffield, UK., Thaçi D; Institute and Comprehensive Center of Inflammation Medicine, University of Lübeck, Lübeck, Germany., Eichenfield LF; Departments of Dermatology, University of California San Diego School of Medicine, San Diego, CA, USA., Arkwright PD; Lydia Becker Institute of Immunology and Inflammation, University of Manchester, Manchester, UK., Sun X; Regeneron Pharmaceuticals, Inc., Basking Ridge, NJ, USA., Chen Z; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Akinlade B; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Boklage S; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Guillemin I; Sanofi, Chilly Mazarin, France., Kosloski MP; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Kamal MA; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., O'Malley JT; Sanofi, Cambridge, MA, USA., Patel N; Sanofi, Cambridge, MA, USA., Graham NMH; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Bansal A; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA. |
| Source: | The British journal of dermatology [Br J Dermatol] 2021 May; Vol. 184 (5), pp. 857-870. Date of Electronic Publication: 2020 Oct 09. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 0004041 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2133 (Electronic) Linking ISSN: 00070963 NLM ISO Abbreviation: Br J Dermatol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
